A gene therapy pioneer moves from Biogen to Regenxbio, staying focused on gene therapy 2.0
Olivier Danos’ arrival as head of Biogen’s gene therapy group two-and-a-half years ago signaled an important shift in the big biotech’s R&D focus. In swift order Biogen executed a partnership with the San Raffaele-Telethon Institute for Gene Therapy, inked a $1 billion-plus deal with AGTC and followed up with a $2 billion pact to work with James Wilson and Jean Bennett at the University of Pennsylvania.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
